Development
AbCellera Biologics Inc.
ABCL
$4.59
$0.092.00%
NASDAQ
12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Revenue | -92.17% | -91.65% | -71.38% | -62.98% | 29.37% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -92.17% | -91.65% | -71.38% | -62.98% | 29.37% |
Cost of Revenue | -64.98% | -60.09% | -51.72% | -50.48% | -15.63% |
Gross Profit | -98.42% | -105.46% | -80.40% | -68.32% | 47.45% |
SG&A Expenses | 12.61% | 9.19% | 15.44% | 22.51% | 37.07% |
Depreciation & Amortization | 25.46% | 23.87% | 31.47% | 38.53% | 34.55% |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 5.65% | -6.15% | 6.64% | 12.98% | 52.59% |
Operating Income | -205.47% | -159.71% | -139.96% | -123.92% | 9.98% |
Income Before Tax | -172.79% | -144.15% | -125.02% | -113.82% | 9.10% |
Income Tax Expenses | -134.29% | -125.92% | -96.48% | -87.68% | 22.67% |
Earnings from Continuing Operations | -192.35% | -152.00% | -136.89% | -124.49% | 3.29% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -192.35% | -152.00% | -136.89% | -124.49% | 3.29% |
EBIT | -205.47% | -159.71% | -139.96% | -123.92% | 9.98% |
EBITDA | -187.09% | -150.38% | -130.09% | -115.34% | 11.60% |
EPS Basic | -190.59% | -151.19% | -136.29% | -124.17% | -0.55% |
Normalized Basic EPS | -171.16% | -141.40% | -121.18% | -110.86% | 8.07% |
EPS Diluted | -205.69% | -157.46% | -143.50% | -129.20% | 3.62% |
Normalized Diluted EPS | -179.01% | -145.32% | -125.05% | -113.63% | 13.53% |
Average Basic Shares Outstanding | 1.44% | 1.45% | 1.65% | 2.41% | 3.38% |
Average Diluted Shares Outstanding | -3.48% | -5.16% | 0.04% | 0.75% | 2.02% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |